Metabolism of brorphine, chlorphine, fluorphine and N-propionitrile chlorphine in human hepatocytes and authentic N-propionitrile chlorphine case studies using high-resolution mass spectrometry

In the shadow of the well-known opioid crisis, a quieter but equally dangerous wave of new synthetic drugs has begun to emerge. These are not the familiar painkillers of the past, but a rapidly evolving family of substances engineered in laboratories to bind tightly to the brain's pain receptors, often with lethal consequences. Among the newest arrivals are a group of compounds known as orphines. These molecules share a specific chemical skeleton, a core structure that allows them to act as powerful keys to the body's opioid locks. Because these drugs are so potent and change so quickly, they pose a severe challenge to doctors and forensic scientists. When a person overdoses, the body often breaks down the original drug so thoroughly that the parent compound vanishes from the bloodstream and urine within hours, leaving behind only a trail of invisible fragments. To identify who took what, and to understand the risks, scientists must map exactly how the human body dismantles these molecules. Without this map, a toxicology test might come back negative even when a person has been exposed to a deadly substance.

A team of researchers at Linköping University in Sweden has now drawn a detailed map for four of these emerging orphines: brorphine, chlorphine, fluorphine, and a particularly notorious variant called N-propionitrile chlorphine. To see how these drugs behave inside a living system, the scientists did not rely on animal models or computer guesses. Instead, they used a collection of human liver cells, the body's primary chemical processing plant. They placed these cells in a controlled environment and introduced the drugs, allowing the cells to process them just as a human liver would. By using highly sensitive mass spectrometry, a technique that weighs molecules with extreme precision, the team tracked every chemical change that occurred. They looked for the specific fragments the liver produced, identifying the new shapes the drugs took as they were broken down and prepared for excretion.

The study revealed that the human liver treats these four drugs with surprising consistency, though with one notable exception. For brorphine, chlorphine, and fluorphine, the liver performed a set of standard chemical operations. It stripped away certain side chains, added oxygen atoms to the core structure, and sometimes attached sugar-like molecules to make the drug easier to flush out. In total, the researchers identified eleven distinct breakdown products for both brorphine and chlorphine, and twelve for fluorphine. A common theme emerged across all three: the liver frequently removed a specific part of the molecule attached to a ring structure, creating what is known as a "nor-metabolite." This process happened so efficiently that in some cases, the original drug was almost completely gone, replaced entirely by these new, smaller versions. The researchers also found that the liver often added oxygen to a specific section of the molecule called the benzimidazolone unit, a central hub where chemical changes tend to cluster.

N-propionitrile chlorphine, however, told a slightly different story. While it shared some of the same breakdown patterns as its cousins, it also underwent unique transformations. The liver cleaved off a specific chemical group to turn it into chlorphine, a process that did not happen with the other three drugs. Furthermore, this drug produced a wider variety of breakdown products, with thirteen distinct metabolites identified in the liver cell experiments. When the team looked at real-world samples from people who had been poisoned by N-propionitrile chlorphine, the pattern held true. In blood samples, they found three of the liver's breakdown products, and in urine, they found even more, including a mix of the original drug's fragments and versions that had been further processed by the body. One specific breakdown product, formed by removing a side chain, appeared in such high amounts in the urine that it stood out as a reliable signal of exposure, even when the original drug was undetectable.

The most critical takeaway from this work is a shift in how these drugs should be hunted in a forensic setting. Because the liver is so effective at destroying the parent compounds, looking for the original drug in urine is often a losing battle; it may have vanished entirely, leading to a false conclusion that no drug was present. The researchers propose that the solution lies in looking for the "nor-metabolites" instead. These are the stripped-down versions of the drugs that the liver creates in large quantities. By testing for these specific fragments, toxicologists can catch exposures that would otherwise be missed. For the specific case of N-propionitrile chlorphine, the study suggests that testing urine without first breaking down the complex sugar attachments might miss key evidence, but analyzing the sample after a simple enzymatic treatment reveals a clear signature of the drug's presence.

This research provides a vital toolkit for the future of drug safety. By understanding exactly how the human body dismantles these new threats, scientists can design better tests that look for the right chemical footprints. The study confirms that while these drugs are chemically diverse, the human body processes them through a few predictable pathways. The identification of these specific breakdown products means that forensic labs can now update their screening methods to include these markers. This change is essential for ensuring that cases of intoxication are correctly identified, allowing for appropriate medical treatment and a clearer understanding of the dangers these substances pose to public health. The work does not solve the problem of the drugs themselves, but it solves the problem of seeing them, turning a blind spot in forensic science into a clear window.